— BioCryst Pharmaceuticals (NASDAQ: BCRX) reported a loss of $0.02 per share for the fourth quarter of 2019 vs. expected loss of $0.26 per share.
— Revenue was $39.7 million vs. $2.7 million in the fourth quarter of 2018 and targeted revenue of $9.88 million.
— R&D expenses increased to $26.8 million from $23.4 million in the prior-year quarter.
— For full-year 2020, operating cash use is expected to be in the range of $125 million to $150 million and operating expenses are estimated to be between $135 million and $160 million.
— On February 18, 2020, the company announced that the U.S. Food and Drug Administration (FDA) had accepted and filed its new drug application (NDA) for the approval of oral, once-daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.
— BioCryst expects Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to approve its berotralstat drug for the prophylactic treatment of HAE in the second half of 2020.
— BCRX stock rose about 7% in the pre-market trading session.
Most Popular
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the
Colgate-Palmolive (CL) Q1 2025 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its first quarter 2025 earnings results today. Net sales decreased 3.1% year-over-year to $4.9 billion. Organic sales growth was 1.4%. Net income attributable to Colgate-Palmolive Company rose
Meta Platforms (META) set to report Q1 earnings. Here’s what to expect
After integrating artificial intelligence into its products, Meta Platforms, Inc. (NASDAQ: META) is investing heavily in the metaverse project. Yet, the tech giant has maintained healthy cash flows and consistently
